CCND1 and breast carcinoma: Thus, given that melatonin acts as a proteasome inhibitor, its effects on the inhibition of cyclin D1 and E, CDK2, CDK4 and c-Myc expression in brain cancer stem cells [91] or on the reduction of cyclin D1 and E expression in breast cancer cells [92,93] could be closely linked.